Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- EMERALDIndependent statistical analysis of Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE: primary endpoint results, effect estimate with confidence interval,…
- EMERALD-2Independent statistical analysis of A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- EMERGEIndependent statistical analysis of Microenterprise Intervention to Reduce Sexual Risk Behaviors in Young Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03766165).
- EMERGEIndependent statistical analysis of A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory…
- Emergence Agitation and Pain Scores in Pediatrics When Comparing Single-modal vs Multi-modal Analgesia for ENT Surgery: Complete Statistical AnalysisIndependent statistical analysis of Emergence Agitation and Pain Scores in Pediatrics When Comparing Single-modal vs Multi-modal Analgesia for ENT Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Emergence Agitation Between Dexmedetomidine and Sevoflurane Anesthesia: Complete Statistical AnalysisIndependent statistical analysis of Emergence Agitation Between Dexmedetomidine and Sevoflurane Anesthesia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06482125).
- Emervel® Deep Lidocaine vs. Juvederm® Ultra Plus in Treatment of Moderate to Severe Facial Wrinkles and Folds: Complete Statistical AnalysisIndependent statistical analysis of Emervel® Deep Lidocaine vs. Juvederm® Ultra Plus in Treatment of Moderate to Severe Facial Wrinkles and Folds: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- EMILIAIndependent statistical analysis of A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- EMIXIndependent statistical analysis of Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01352585).
- Emla-Cream as Pain Relief During Pneumococcal Vaccination: Complete Statistical AnalysisIndependent statistical analysis of Emla-Cream as Pain Relief During Pneumococcal Vaccination: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01802086).
- EMMYIndependent statistical analysis of Effectiveness of Quetiapine XR on the Control of Symptoms of Manic Phase of Bipolar Disorder.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Emotion Regulation Interventions for Alcohol-Related Sexual Aggression: Complete Statistical AnalysisIndependent statistical analysis of Emotion Regulation Interventions for Alcohol-Related Sexual Aggression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03159468).
- EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin): Complete Statistical AnalysisIndependent statistical analysis of EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03594110).
- EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction): Complete Statistical AnalysisIndependent statistical analysis of EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction): primary endpoint results,…
- EMPACTAIndependent statistical analysis of A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus: Complete Statistical AnalysisIndependent statistical analysis of Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus: Complete Statistical AnalysisIndependent statistical analysis of Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3): Complete Statistical AnalysisIndependent statistical analysis of Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved): Complete Statistical AnalysisIndependent statistical analysis of EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- EMPATHYIndependent statistical analysis of A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- EMPEROR-ReducedIndependent statistical analysis of EMPEROR-Reduced, a randomized phase 3 trial of empagliflozin versus placebo in chronic heart failure with reduced ejection fraction. Includes the registered time-to-event endpoint, Cox and mixed-effects analyses, reported…
- EMPiREIndependent statistical analysis of GORE Embolic Protection With Reverse Flow: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00594100).
- EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients: Complete Statistical AnalysisIndependent statistical analysis of EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients: primary endpoint results, effect estimate with confidence…
- EMPOWER-EDIndependent statistical analysis of Promoting Benzodiazepine Cessation Through an Electronically-delivered Patient Self-management Intervention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04572750).
- EMPOWER-T2DIndependent statistical analysis of EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04531176).
- Empowering LGBTQ+ Tobacco Cessation Pilot: Complete Statistical AnalysisIndependent statistical analysis of Empowering LGBTQ+ Tobacco Cessation Pilot: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05365633).
- EMRI SureScan™ Clinical Study: Complete Statistical AnalysisIndependent statistical analysis of EMRI SureScan™ Clinical Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00433654).
- ENAC Blockade and Arterial Stiffness: Complete Statistical AnalysisIndependent statistical analysis of ENAC Blockade and Arterial Stiffness: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03837626).
- Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation: Complete Statistical AnalysisIndependent statistical analysis of Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05282459).
- Encapsulated Juice Powder Concentrate for Preventing Common Cold Symptoms: Complete Statistical AnalysisIndependent statistical analysis of Encapsulated Juice Powder Concentrate for Preventing Common Cold Symptoms: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00778648).
- ENCOREIndependent statistical analysis of A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE): primary endpoint results, effect estimate with confidence…
- ENCOREIndependent statistical analysis of Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- ENCORE-VTIndependent statistical analysis of Phase I/II Study of EP-guided Noninvasive Cardiac Radioablation for Treatment of Ventricular Tachycardia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- ENDEAVORIndependent statistical analysis of the ENDEAVOR phase 3 trial of carfilzomib and dexamethasone versus bortezomib and dexamethasone in relapsed multiple myeloma, including progression-free survival, overall survival, response, safety, and statistical methodology.
- ENDEAVORIndependent statistical analysis of Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Endoesophageal Brachytherapy for Patients With Esophageal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Endoesophageal Brachytherapy for Patients With Esophageal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03335813).
- Endometrial Injury for Unexplained Infertility: Complete Statistical AnalysisIndependent statistical analysis of Endometrial Injury for Unexplained Infertility: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02863198).
- Endometrial Scratch Effect on Pregnancy Rates in Patients Undergoing Egg-donation IVF: Complete Statistical AnalysisIndependent statistical analysis of Endometrial Scratch Effect on Pregnancy Rates in Patients Undergoing Egg-donation IVF: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- ENDORSEIndependent statistical analysis of BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Endoscopic Abraxane Injection Into Pancreatic Cysts: Complete Statistical AnalysisIndependent statistical analysis of Endoscopic Abraxane Injection Into Pancreatic Cysts: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01698710).
- Endoscopic Suturing System for Tissue Apposition: Complete Statistical AnalysisIndependent statistical analysis of Endoscopic Suturing System for Tissue Apposition: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00495222).
- Endoscopic Trigger Finger Release: Complete Statistical AnalysisIndependent statistical analysis of Endoscopic Trigger Finger Release: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03883477).
- EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX: Complete Statistical AnalysisIndependent statistical analysis of EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Endothelial Function in Lower Extremity Bypass Grafts: Complete Statistical AnalysisIndependent statistical analysis of Endothelial Function in Lower Extremity Bypass Grafts: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00759707).
- Endothelin-1 and Cardiac Allograft Vasculopathy (CAV): Complete Statistical AnalysisIndependent statistical analysis of Endothelin-1 and Cardiac Allograft Vasculopathy (CAV): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05373108).
- Endotrol-tracheal Tube Assisted Endotracheal Intubation During Video Laryngoscopy: Complete Statistical AnalysisIndependent statistical analysis of Endotrol-tracheal Tube Assisted Endotracheal Intubation During Video Laryngoscopy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01099969).
- Endovascular Exclusion of Abdominal Aortic Aneurysms in High Risk Patients: Complete Statistical AnalysisIndependent statistical analysis of Endovascular Exclusion of Abdominal Aortic Aneurysms in High Risk Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00583414).
- ENDURANCE-2Independent statistical analysis of A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection: primary endpoint results, effect estimate with confidence…
- Endurant Evo US Clinical Trial: Complete Statistical AnalysisIndependent statistical analysis of Endurant Evo US Clinical Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02393716).